Crossmark

Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response

Crossref DOI link: https://doi.org/10.1186/s12890-018-0689-2

Published Online: 2018-07-18

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Drick, Nora https://orcid.org/0000-0002-2066-0941
Seeliger, Benjamin

Welte, Tobias

Fuge, Jan

Suhling, Hendrik
License Information

Text and Data Mining valid from 2018-07-18
More Information

Article History

Received: 12 March 2018

Accepted: 10 July 2018

First Online: 18 July 2018

Ethics approval and consent to participate

: All patients under follow-up at our asthma outpatient clinic provided written informed consent. The study was approved by the Internal Ethics Review Board of Hannover Medical School.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.